OmniMetrix is most often covered alongside Acorn Energy, Inc., which appears in 2 of these 2 stories. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about OmniMetrix
OmniMetrix is most often covered alongside Acorn Energy, Inc., which appears in 2 of these 2 stories. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention OmniMetrix, all published on March 6, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering OmniMetrix. Shared-story counts are live from our verified record — not editorial picks.
Acorn Energy and CorMedix both reported Q4 2025 financial results on March 5, 2026, marking a critical transition from development to commercial scaling. While Acorn focuses on high-margin IoT recurring revenue, CorMedix is navigating the complex rollout of its lead product, DefenCath, in the dialysis market.
CorMedix and Acorn Energy reported strong Q4 2025 results, highlighting a year of significant commercial expansion for specialized healthcare and infrastructure solutions. CorMedix saw accelerated adoption of its antimicrobial catheter lock solution, DefenCath, while Acorn Energy’s OmniMetrix division capitalized on rising demand for remote monitoring in critical healthcare facilities.